Early doxorubicin cardiotoxicity in Malawian children admitted to Queen Elizabeth Central Hospital, Malawi

Doxorubicin is known to cause chemotherapy‐induced cardiotoxicity. In resource‐poor settings, monitoring for cardiotoxicity is not routinely done, and its incidence is unknown. The aim of this study was to determine the proportion of children who developed doxorubicin‐induced cardiotoxicity within 1 year of having received treatment at paediatric oncology ward.

[1]  Jeroen J. Bax,et al.  2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines , 2016, European journal of heart failure.

[2]  C. Criscitiello,et al.  Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management , 2016, CA: a cancer journal for clinicians.

[3]  E. A. Greene,et al.  Development of a subspecialty cardiology curriculum for paediatric registrars in Malawi: Implementation of a long-distance hybrid model. , 2016, Malawi medical journal : the journal of Medical Association of Malawi.

[4]  G. Curigliano,et al.  Early Detection of Anthracycline Cardiotoxicity and Improvement With Heart Failure Therapy , 2015, Circulation.

[5]  M. Cerqueira,et al.  Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. , 2014, European heart journal cardiovascular Imaging.

[6]  S. Lipshultz,et al.  Anthracycline-Induced Cardiotoxicity: A Review of Pathophysiology, Diagnosis, and Treatment , 2014, Current Treatment Options in Cardiovascular Medicine.

[7]  Munir Pirmohamed,et al.  Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology , 2011, European journal of heart failure.

[8]  K. Dilley,et al.  Anthracycline-induced Cardiac Toxicity More Likely in Underweight Childhood Cancer Survivors , 2010, Journal of pediatric hematology/oncology.

[9]  S. Colan,et al.  Recommendations for quantification methods during the performance of a pediatric echocardiogram: a report from the Pediatric Measurements Writing Group of the American Society of Echocardiography Pediatric and Congenital Heart Disease Council. , 2010, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[10]  T. Israels,et al.  Paediatric oncology in the Queen Elizabeth Hospital, Blantyre. , 2008, Malawi medical journal : the journal of Medical Association of Malawi.

[11]  Mark F. Lutz,et al.  Monitoring of Anthracycline-Induced Cardiotoxicity , 2008, The Annals of pharmacotherapy.

[12]  G. Liomba,et al.  Spectrum and presentation of pediatric malignancies in the HIV era: Experience from Blantyre, Malawi, 1998–2003 , 2007, Pediatric blood & cancer.

[13]  S. Lipshultz.  Exposure to anthracyclines during childhood causes cardiac injury. , 2006, Seminars in oncology.

[14]  K. Sridhar,et al.  Detection of Early Anthracycline Cardiotoxicity by Monitoring the Peak Filling Rate , 1993, American journal of clinical oncology.

[15]  M. Ferrière,et al.  [Cardiotoxicity of anthracyclines]. , 1993, Archives des maladies du coeur et des vaisseaux.

[16]  S. Lipshultz,et al.  Anthracycline-induced cardiotoxicity in children and young adults. , 1998, Critical reviews in oncology/hematology.